-
G288503-100mgSelective LPA2receptor non-lipid agonist.
-
G288503-10mgSelective LPA2receptor non-lipid agonist.
-
G288503-25mgSelective LPA2receptor non-lipid agonist.
-
G288503-50mgSelective LPA2receptor non-lipid agonist.
-
G288503-5mgSelective LPA2receptor non-lipid agonist.
-
G286912-100mgProduct descriptionGRL0617 is a selective and competitive noncovalent inhibitor of severe acute respiratory syndrome (SARS-CoV) papain-like protease (PLpro), with an IC50 of 0.6 μM and a Ki value of 0.49 μM. GRL0617 also inhibits SARS-CoV with an
-
G286912-10mgProduct descriptionGRL0617 is a selective and competitive noncovalent inhibitor of severe acute respiratory syndrome (SARS-CoV) papain-like protease (PLpro), with an IC50 of 0.6 μM and a Ki value of 0.49 μM. GRL0617 also inhibits SARS-CoV with an
-
G286912-25mgProduct descriptionGRL0617 is a selective and competitive noncovalent inhibitor of severe acute respiratory syndrome (SARS-CoV) papain-like protease (PLpro), with an IC50 of 0.6 μM and a Ki value of 0.49 μM. GRL0617 also inhibits SARS-CoV with an
-
G286912-50mgProduct descriptionGRL0617 is a selective and competitive noncovalent inhibitor of severe acute respiratory syndrome (SARS-CoV) papain-like protease (PLpro), with an IC50 of 0.6 μM and a Ki value of 0.49 μM. GRL0617 also inhibits SARS-CoV with an
-
G286912-5mgProduct descriptionGRL0617 is a selective and competitive noncovalent inhibitor of severe acute respiratory syndrome (SARS-CoV) papain-like protease (PLpro), with an IC50 of 0.6 μM and a Ki value of 0.49 μM. GRL0617 also inhibits SARS-CoV with an
-
-